

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet **1** of **27****Complete if Known**

Application Number	10/544,093
Filing Date	August 1, 2005
First Named Inventor	Yednock, Ted
Art Unit	1649
Examiner Name	Emch, Gregory
Attorney Docket Number	15270C-009820US

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	945	2008/0050367 A1	02-28-2008	Basi et al.	
	944	2007/0238154 A1	10-11-2007	Basi et al.	
	943	2007/0154480 A1	07-05-2007	Schenk et al.	
	855	7,195,761	03-27-2007	Holtzman et al.	
	878	7,189,819	03-13-2007	Basi et al.	
	879	7,179,892	02-20-2007	Basi et al.	
	946	2006/0280743 A1	12-14-2006	Basi et al.	
	880	7,014,855	03-21-2006	Schenk	
	881	6,982,084	01-03-2006	Schenk	
	686	6,972,127	12-06-2005	Schenk	
	879	7,179,892	02-20-2007	Basi et al.	
	679	2005/0255122 A1	11-17-2005	Schenk	
	680	2005/0249727 A1	11-10-2005	Schenk	
	785	2005/0249725 A1	11-10-2005	Schenk et al.	
	866	6,962,984	11-08-2005	Ishiwata et al.	
	674	6,962,707	11-08-2005	Schenk	
	656	6,946,135	09-20-2005	Schenk	
	949	2005/0196399 A1	09-08-2005	Schenk et al.	
	693	2005/0191314 A1	09-01-2005	Schenk	
	713	6,936,698	08-30-2005	Taylor	
	716	6,933,368	08-23-2005	Co et al.	
	758	2005/0169925 A1	08-04-2005	Bardroff et al.	
	892	6,923,964	08-02-2005	Schenk	
	685	2005/0163788 A1	07-28-2005	Schenk	
	884	2005/0152878 A1	07-14-2005	Solomon et al.	
	657	6,913,745	07-05-2005	Schenk	
	715	2005/0136054 A1	06-23-2005	Adair et al.	
	658	6,905,686	06-14-2005	Schenk	
	714	2005/0123534 A1	06-09-2005	Adair et al.	
	784	2005/0118651 A1	06-02-2005	Basi et al.	
	659	6,890,535	05-10-2005	Schenk	
	683	2005/0059802 A1	03-17-2005	Schenk et al.	
	684	2005/0059591 A1	03-17-2005	Schenk et al.	
	661	2005/0009150 A1	01-13-2005	Basi et al.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
(Use as many sheets as necessary)		Attorney Docket Number	15270C-009820US
Sheet	2	of	27

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (if known)			
	673	6,808,712	10-26-2004	Schenk	
	805	2004/0197324 A1	10-07-2004	Jun et al.	
	667	6,787,523	09-07-2004	Schenk	
	670	6,787,144	09-07-2004	Schenk	
	668	6,787,143	09-07-2004	Schenk	
	672	6,787,140	09-07-2004	Schenk	
	882	6,787,139	09-07-2004	Schenk	
	669	6,787,138	09-07-2004	Schenk	
	671	6,787,129	09-07-2004	Schenk	
	660	2004/0171815 A1	09-02-2004	Schenk et al.	
	783	2004/0087777 A1	05-06-2004	Basi et al.	
	782	2004/0082762 A1	04-29-2004	Basi et al.	
	849	6,727,349	04-27-2004	LaRosa et al.	
	870	2003/0207828 A1	11-06-2003	Ishiwata et al.	
	708	2003/0039645 A1	10-14-2003	Adair et al.	
	675	6,710,226	03-23-2004	Schenk	
	804	2003/0202972 A1	10-30-2003	James et al.	
	712	6,639,055	10-28-2003	Carter et al.	
	709	6,632,927	10-14-2003	Adair et al.	
	748	6,610,493	08-26-2003	Citron et al.	
	730	2003/0166557 A1	09-04-2003	Minna et al.	
	869	2003/0135035 A1	07-17-2003	Shannon	
	883	6,582,945	06-24-2003	Raso	
	871	2003/0092145 A1	05-15-2003	Jira et al.	
	702	6,548,640	04-15-2003	Winter	
	725	6,538,124	03-25-2003	Idusogie et al.	
	726	6,528,624	03-04-2003	Idusogie et al.	
	710	6,407,213	06-18-2002	Carter et al.	
	776	6,372,716	04-16-2002	Bush et al.	
	906	6,339,068	01-15-2002	Krieg et al.	
	720	6,277,375	08-21-2001	Ward	
	777	6,270,757	08-07-2001	Wame	
	778	6,267,958	07-31-2001	Andya et al.	
	795	6,210,671	04-03-2001	Co	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
(Use as many sheets as necessary)		Attorney Docket Number	15270C-009820US
Sheet	3	of	27

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number Kind Code ² (If Known)			
	724	6,194,551	02-27-2001	Idusogie et al.	
	704	6,180,370	01-30-2001	Queen et al.	
	747	6,175,057	01-16-2001	Mucke et al.	
	719	6,165,745	12-26-2000	Ward et al.	
	723	6,121,022	09-19-2000	Presta et al.	
	711	6,054,297	04-25-2000	Carter et al.	
	905	5,994,083	11-30-1999	Felici et al.	
	722	5,869,046	02-09-1999	Presta et al.	
	867	5,866,129	02-02-1999	Chang et al.	
	707	5,859,205	01-12-1999	Adair et al.	
	860	5,858,981	01-12-1999	Schreiber et al.	
	771	5,837,268	11-17-1998	Potter et al.	
	885	5,798,102	08-25-1998	McMichael et al.	
	779	5,770,700	06-23-1998	Webb et al.	
	780	5,744,132	04-28-1998	Wame et al.	
	770	5,733,548	03-31-1998	Restifo et al.	
	876	5,731,284	03-24-1998	Williams	
	642	5,702,906	12-30-1997	Rosenthal	
	643	5,693,762	12-02-1997	Queen et al.	
	705	5,693,761	12-02-1997	Queen et al.	
	721	5,677,425	10-14-1997	Bodmer et al.	
	717	5,648,260	07-15-1997	Winter et al.	
	924	5,624,937	04-29-1997	Reel et al.	
	718	5,624,821	04-29-1997	Winter et al.	
	644	5,618,920	04-08-1997	Robinson et al.	
	764	5,601,827	02-11-1997	Collier et al.	
	706	5,585,089	12-17-1996	Queen et al.	
	619	5,530,101	06-25-1996	Queen et al.	
	781	5,385,887	01-31-1995	Yim et al.	
	645	5,258,498	11-02-1993	Huston et al.	
	868	5,245,015	09-14-1993	Fung et al.	
	819	5,227,159	07-13-1993	Miller	
	703	5,225,539	07-06-1993	Winter	
	740	4,883,666	11-28-1989	Sabel et al.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/544,093
				Filing Date	August 1, 2005
				First Named Inventor	Yednock, Ted
				Art Unit	1649
				Examiner Name	Emch, Gregory
(Use as many sheets as necessary)				Attorney Docket Number	15270C-009820US
Sheet	4	of	27		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	646	4,816,567	03-28-1989	Cabilly et al.	
	647	4,816,397	03-28-1989	Boss et al.	
U.S. PATENT APPLICATIONS					
Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	899	11/358,951	02-22-2006	Solomon et al.	
	691	11/245,524	10-07-2005	Schenk	
	692	11/245,916	10-07-2005	Schenk	
	948	60/251,892	12-06-2000	Basi et al.	
	762	60/080,970	01-11-1999	Schenk	
	761	60/079,697	03-27-1998	Weiner et al.	
	763	60/067,740	12-02-1997	Schenk	
	760	60/067,219	12-03-1997	Weiner et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁴
	853	EP	921 189	B1	01-12-2005			<input type="checkbox"/>
	842	EP	1 481 992	A2, A3	12-01-2004			<input type="checkbox"/>
	786	EP	758 901	B1	02-26-1997			<input type="checkbox"/>
	787	EP	758 248	B1	02-19-1997			<input type="checkbox"/>
	738	EP	626 390	A1	11-30-1994			<input type="checkbox"/>
	737	EP	620 276	A1	10-19-1994			<input type="checkbox"/>
	802	EP	597 101	A1	05-18-1994			<input type="checkbox"/>
	921	EP	0 391 714	A2	10-10-1990			<input type="checkbox"/>
	820	EP	285 159	A1	10-05-1988			<input type="checkbox"/>
	632	JP	07-132033	A	05-23-1995			<input type="checkbox"/>
	631	JP	62-267297	A	11-19-1987			<input type="checkbox"/>
	848	WO	05/026211	A2, A3	03-24-2005			<input type="checkbox"/>
	701	WO	05/014041	A2	02-17-2005			<input type="checkbox"/>
	757	WO	04/108895	A2, A3	12-16-2004			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Application Number	10/544,093	
			Filing Date	August 1, 2005	
			First Named Inventor	Yednock, Ted	
			Art Unit	1649	
			Examiner Name	Emch, Gregory	
(Use as many sheets as necessary)					
Sheet	5	of	27	Attorney Docket Number	15270C-009820US

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†*
		Country Code ²	Number ⁴	Kind Code ³ (if known)				
	935	WO	04/080419	A3	09-23-2004			<input type="checkbox"/>
	847	WO	04/071408	A2	08-26-2004			<input type="checkbox"/>
	918	WO	04/069182	A2	08-19-2004			<input type="checkbox"/>
	797	WO	04/055164	A2	07-01-2004			<input type="checkbox"/>
	846	WO	04/044204	A2, A3	05-27-2004			<input type="checkbox"/>
	796	WO	03/105894	A1	12-24-2003			<input type="checkbox"/>
	845	WO	03/072036	A2, A3	09-04-2003			<input type="checkbox"/>
	799	WO	03/39485	A2	05-15-2003			<input type="checkbox"/>
	756	WO	03/16467	A2, A3	02-27-2003			<input type="checkbox"/>
	803	WO	03/16466	A2	02-27-2003			<input type="checkbox"/>
	788	WO	03/15691	A2	02-27-2003			<input type="checkbox"/>
	798	WO	03/09817	A2	02-06-2003			<input type="checkbox"/>
	827	WO	02/96937	A2	12-05-2002			<input type="checkbox"/>
	934	WO	02/46237	A3	06-13-2002			<input type="checkbox"/>
	789	WO	01/05355	A2	01-25-2001			<input type="checkbox"/>
	772	WO	99/10008	A1	03-04-1999			<input type="checkbox"/>
	813	WO	97/03192	A3	01-30-1997			<input type="checkbox"/>
	633	WO	96/08565	A2	03-21-1996			<input type="checkbox"/>
	923	WO	95/23860	A2	09-08-1995			<input type="checkbox"/>
	630	WO	95/17085	A1	06-29-1995			<input type="checkbox"/>
	854	WO	95/07301	A1	03-16-1995			<input type="checkbox"/>
	696	WO	95/06407	A1	03-09-1995			<input type="checkbox"/>
	736	WO	94/10569	A1	05-11-1994			<input type="checkbox"/>
	922	WO	94/09364	A1	04-28-1994			<input type="checkbox"/>
	814	WO	94/00153	A1	01-06-1994			<input type="checkbox"/>
	947	WO	92/22653	A1	12-23-1992			<input type="checkbox"/>
	821	WO	91/16928	A1	11-14-1991			<input type="checkbox"/>
	648	WO	91/09967	A1	07-11-1991			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	6	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	927	AISEN, P., "Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Strategies," <u>Gerontology</u> , 43:143-149 (1997).	<input type="checkbox"/>
	912	AKIYAMA et al., "The amino-terminally truncated forms of amyloid β -protein in brain macrophages in the ischemic lesions of Alzheimer's disease patients," <u>Neuroscience Letters</u> , 219:115-118 (1996).	<input type="checkbox"/>
	663	ALBERTS et al., eds. <i>Molecular Biology of The Cell, Third Edition</i> , chapter 23, pages 1208-1209 (1994).	<input type="checkbox"/>
	773	ALBERTS ET AL., <i>Molecular Biology of the Cell, 2nd Edition</i> , pages 266-267, Garland Publishing Inc., New York (1989).	<input type="checkbox"/>
	649	AMIT et al., "Three-Dimensional Structure of an Antigen-Antibody Complex at 2.8 Å Resolution," <u>Science</u> , 233:747-753 (1986).	<input type="checkbox"/>
	588	ANDERSON, J. P., "Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells," <u>Neuroscience Letters</u> , 128(1):126-128 (1991).	<input type="checkbox"/>
	589	ANDERSON, M. W., "Amending the amyloid hypothesis," <u>The Scientist</u> , 18(20):28-29 (2004).	<input type="checkbox"/>
	677	ANKARCORONA et al., "Biomarkers for apoptosis in Alzheimer's disease," <u>Int. J. Geriatric Psychiatry</u> , 20:101-105 (2005).	<input type="checkbox"/>
	875	ARD et al., "Scavenging of Alzheimer's Amyloid β -Protein by Microglia in Culture," <u>J. Neuroscience Research</u> , 43:190-202 (1996).	<input type="checkbox"/>
	898	ASKELOF et al., "Protective immunogenicity of two synthetic peptides selected from the amino acid sequence of <i>Bordetella pertussis</i> toxin subunit S1," <u>PNAS</u> , 87:1347-1351 (1990).	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		<i>Application Number</i>	10/544,093
		<i>Filing Date</i>	August 1, 2005
		<i>First Named Inventor</i>	Yednock, Ted
		<i>Art Unit</i>	1649
		<i>Examiner Name</i>	Emch, Gregory
		<i>Attorney Docket Number</i>	15270C-009820US
Sheet	7	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	681	AULD et al., "Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies," <i>Progress in Neurobiol.</i> , 68:209-245 (2002).	<input type="checkbox"/>
	590	BACSKAI et al., "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy," <i>J. Neurosci.</i> , 22(18):7873-7878 (2002).	<input type="checkbox"/>
	790	BALES et al., "Administration of an Anti-A β Fab Fragment to APP ^{V717F} Transgenic Mice Reduces Neuritic Plaque," Abstract P4-396, presented at Poster Session P4: Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, <i>Neurology of Aging</i> , 25:S587 (2004).	<input type="checkbox"/>
	858	BALES et al., "Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A β antibody," <i>J. Clin. Invest.</i> , 116(3):825-832 (2006).	<input type="checkbox"/>
	911	BEN-YEDIDIA et al., "Design of peptide and polypeptide vaccines," <i>Current Opinion in Biotechnology</i> , 8:442-448 (1997).	<input type="checkbox"/>
	750	BICKEL et al., "Development and in Vitro Characterization of a Cationized Monoclonal Antibody against β A4 Protein: A Potential Probe for Alzheimer's Disease," <i>Bioconjugate Chem.</i> , 5:119-125 (1994).	<input type="checkbox"/>
	754	BLASBERG et al., "Regional Localization of Glioma-associated Antigen Defined by Monoclonal Antibody 81C6 in Vivo: Kinetics and Implications for Diagnosis and Therapy," <i>Cancer Research</i> , 47:4432-4443 (1987).	<input type="checkbox"/>
	840	BORENSTEIN, S., "New Alzheimer's vaccine to be tested on people soon, Early experiments on mice halted condition; considered safe for humans," <i>Free Press</i> , 7/23/01.	<input type="checkbox"/>
	746	BRAZIL et al., "Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia," <i>J. Biol. Chem.</i> , 275(22):16941-16947 (2000).	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	8	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	915	BRITT et al., "Formulation of an immunogenic human cytomegalovirus vaccine: responses in mice," <u>J. Infect. Dis.</u> , 171:18-25 Abstract (1995).	<input type="checkbox"/>
	832	BROADWELL et al., "Serum proteins bypass the blood-brain fluid barriers for extracellular entry to the central nervous system," <u>Exp. Neurol.</u> , 120(2):245-263 (1993).	<input type="checkbox"/>
	824	BROOKMEYER et al., "Projections of Alzheimer's Disease in the United States and the Public Health Impact of Delaying Disease Onset," <u>Am. J. Public Health</u> , 88:1337-1342 (1998).	<input type="checkbox"/>
	791	BUSSIERE et al., "Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A β Immunotherapy on Their Clearance," <u>Am. J. Pathology</u> , 165(3):987-995 (2004).	<input type="checkbox"/>
	891	CASADESUS et al., "The Estrogen Myth: Potential Use of Gonadotropin-Releasing Hormone Agonists for the Treatment of Alzheimer's Disease," <u>Drugs R.D.</u> , 7(3):187-193 (2006).	<input type="checkbox"/>
	901	CASEY, S.O., "Posterior Reversible Encephalopathy Syndrome: Utility of Fluid-attenuated Inversion Recovery MR Imaging in the Detection of Cortical and Subcortical Lesions," <u>Amer. J. Neuroradiol.</u> , 21:1199-1206 (2000).	<input type="checkbox"/>
	823	CASELL et al., "Demography and Epidemiology of Age-Associated Neuronal Impairment," chapter 4, pages 31-50 from <u>Functional Neurobiology of Aging</u> , Hof et al., eds., Academic Press (2001).	<input type="checkbox"/>
	932	CHAKRABARTI et al., "Vaccinia Virus Expression Vector: Coexpression of B-Galactosidase Provides Visual Screening of Recombinant Virus Plaques," <u>Molecular and Cellular Biology</u> , 5(12):3403-3409 (1985).	<input type="checkbox"/>
	930	CHANG et al., "Adjuvant activity of incomplete Freund's adjuvant," <u>Advanced Drug Delivery Reviews</u> , 32:173-186 (1998).	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	9	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	639	Chimicon International, "Mouse Anti-Amyloid Beta Protein Monoclonal Antibody," Catalog # MAB1561 (2003-2005).	<input type="checkbox"/>
	591	CHROMY et al., "Self-assembly of A β (1-42) into globular neurotoxins," <i>Biochemistry</i> , 42(44):12749-12760 (2003).	<input type="checkbox"/>
	592	CITRON et al., "Evidence that the 42- and 40- amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities," <i>PNAS</i> , 93(23):13170-13175 (1996).	<input type="checkbox"/>
	593	CITRON, M., "Alzheimer's disease: treatments in discovery and development," <i>Nat. Neurosci.</i> , 5:1055-1057 (2002).	<input type="checkbox"/>
	699	CLAYTON et al., "Synucleins in Synaptic Plasticity and Neurodegenerative Disorders," <i>J. Neurosci. Res.</i> , 58:120-129 (1999).	<input type="checkbox"/>
	766	COICO et al., <i>Immunology A Short Course, Fifth Edition</i> , pages 18-24 (2003).	<input type="checkbox"/>
	925	Colombian Patent Application No. 98071271, Technical Opinion of Jean Paul Vernot submitted on June 22, 2005 as evidence with the brief amending the nullity action (with English translation) (drafted November 2004).	<input type="checkbox"/>
	859	COMERY et al., "Passive Immunization Against β -Amyloid Leads to Acute Cognition Improvement," <i>Society for Neuroscience</i> , abstract, Washington DC, 11/12-16/05.	<input type="checkbox"/>
	908	COREY-BLOOM et al., "Clinical features distinguishing large cohorts with possible AD, probable AD, and mixed dementia," <i>J. Am. Geriatr. Soc.</i> , 41(1):31-37 Abstract (1993).	<input type="checkbox"/>
	687	COX et al., "Adjuvants—a classification and review of their modes of action," <i>Vaccine</i> , 15(3):248-256 (1997).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/544,093	
			Filing Date	August 1, 2005	
			First Named Inventor	Yednock, Ted	
			Art Unit	1649	
			Examiner Name	Emch, Gregory	
Sheet	10	of	27	Attorney Docket Number	15270C-009820US

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	836	DAS et al., "Reduced effectiveness of A β -42 immunization in APP transgenic mice with significant amyloid deposition," <i>Neurobiology of Aging</i> , 22:721-727 (2001).	<input type="checkbox"/>	
	769	DAVIS, S. S., "Nasal Vaccines," <i>Advanced Drug Delivery Reviews</i> , 51:21-42 (2001).	<input type="checkbox"/>	
	861	DE FELICE et al., "A β -Amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease," <i>Cell Mol. Neurobiol.</i> , 22(5/6):545-563 (2002).	<input type="checkbox"/>	
	893	DE LA CRUZ et al., "Immunogenicity [sic] and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage," <i>J Biol Chem</i> , 263(9):4318-4322 (1988).	<input type="checkbox"/>	
	689	DE LUSTIG et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critical Evaluations," <i>Rev. In Neurosciences</i> , 5:213-225 (1994).	<input type="checkbox"/>	
	594	DEMATTOS et al., "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease," <i>Science</i> , 295(5563):2264-2267 (2002).	<input type="checkbox"/>	
	745	DEWITT et al., "Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease," <i>Experimental Neurology</i> , 149:329-340 (1998).	<input type="checkbox"/>	
	698	Dictionary.com definition of "prophylactic", pages 1-3 downloaded from internet 10/12/05.	<input type="checkbox"/>	
	735	DI MARTINO et al., "Production and Characterization of Antibodies to Mouse Scrapie-Amyloid Protein Elicited by Non-carrier Linked Synthetic Peptide Immunogens," <i>J. Molecular Recognition</i> , 4(2-3):85-91 (1991).	<input type="checkbox"/>	
	862	DISIS et al., "Granulocyte-macrophage colony-stimulating factor: An effective adjuvant for protein and peptide-based vaccines," <i>Blood</i> , 88(1):202-210 (1996).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	11	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	595	DODART et al., "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model," <i>Nat. Neurosci.</i> , 5(5):452-457 (2002).	<input type="checkbox"/>
	596	DODEL et al., "Immunotherapy for Alzheimer's disease," <i>Lancet Neurol.</i> , 2(4):215-220 (2003).	<input type="checkbox"/>
	597	DOVEY et al., "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain," <i>J. Neurochem.</i> , 76(1):173-181 (2001).	<input type="checkbox"/>
	910	DREW et al., "Vaccination by cholera toxin conjugated to a herpes simplex virus type 2 glycoprotein D peptide," <i>Journal of General Virology</i> , 73:2357-2366 (1992).	<input type="checkbox"/>
	817	DU et al., " α_2 -Macroglobulin as a β -Amyloid Peptide-Binding Plasma Protein," <i>J. Neurochemistry</i> , 69(1):299-305 (1997).	<input type="checkbox"/>
	598	DUFF et al., "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1," <i>Nature</i> , 383(6602):710-713 (1996).	<input type="checkbox"/>
	920	Ecuador Patent Application No. SP 98-2764, English translation of Expert Report submitted April 19, 2007 in support of the Appeal filed on July 29, 2005.	<input type="checkbox"/>
	599	ERIKSEN et al., "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo," <i>J. Clin. Invest.</i> , 112(3):440-449 (2003).	<input type="checkbox"/>
	811	European Search Report of 5/22/06 for European Application 06075704.4-2107.	<input type="checkbox"/>
	812	European Search Report of 5/22/06 for European Application 06075479.3-2107.	<input type="checkbox"/>
	852	European Search Report of 1/16/07 for European Application 04776252.1-2405.	<input type="checkbox"/>
Examiner Signature			Date Considered

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ³ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/544,093
				Filing Date	August 1, 2005
				First Named Inventor	Yednock, Ted
				Art Unit	1649
				Examiner Name	Emch, Gregory
Sheet	12	of	27	Attorney Docket Number	15270C-009820US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	942	European Examination Report of 03/09/2007 for European Application 01995364.5-1222.	<input type="checkbox"/>
	941	European Examination Report of 09/26/2007 for European Application 04720353.4-1222.	<input type="checkbox"/>
	940	European Examination Report of 10/08/2007 for European Application 01995364.5-1222.	<input type="checkbox"/>
	600	FINDEIS, M. A., "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization," <i>Biochem. Biophys. Acta</i> , 1502(1):76-84 (2000).	<input type="checkbox"/>
	650	FOOTE et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops," <i>J. Mol. Biol.</i> , 224:487-499 (1992).	<input type="checkbox"/>
	830	FOX et al., "Presymptomatic cognitive deficits in individuals at risk of familial Alzheimer's disease," <i>Brain</i> , 121:1631-1639 (1998).	<input type="checkbox"/>
	601	FRENKEL et al., "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization," <i>Vaccine</i> , 21(11-12):1060-1065 (2003).	<input type="checkbox"/>
	602	FRENKEL et al., "Towards Alzheimer's β -amyloid vaccination," <i>Biologicals</i> , 29(3-4):243-247 (2001).	<input type="checkbox"/>
	831	FUKUTANI et al., "Cerebellar pathology in sporadic and familial Alzheimer's disease including APP 717 (Val>Ile) mutation cases: A morphometric investigation," <i>J. Neurologic Sci.</i> , 149:177-184 (1997).	<input type="checkbox"/>
	603	GELINAS et al., "Immunotherapy for Alzheimer's disease," <i>PNAS</i> , 101(suppl. 2):14657-14662 (2004).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	13	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	T ²
	634	Genbank Accession number AAB48800, "Anti-DNA immunoglobulin light chain IgG [Mus musculus]," 09/14/01.	<input type="checkbox"/>
	635	Genbank Accession number CAA46659, "IgE antibody light chain(VJ)," 06/15/93.	<input type="checkbox"/>
	636	Genbank Accession number X65775.1, "M.musculus DNA for IgE antibody light chain (VJ)," 06/15/93.	<input type="checkbox"/>
	637	Genbank Accession number AAD26773, "Immunoglobulin heavy chain VH3609-JH3 region [Mus musculus]," 04/22/99.	<input type="checkbox"/>
	873	GEYLIS et al., "Immunotherapy of Alzheimer's disease 9AD): From murine models to anti-amyloid beta 9Ab) human monoclonal antibodies," <u>Autoimmunity Rev.</u> , 5:33-39 (2000).	<input type="checkbox"/>
	902	GILMAN, S. et al., "Clinical Effects of Aβ Immunization (AN1792) in Patients with AD in an Interrupted Trial," <u>Neurology</u> , 64:1553-1562 (2005).	<input type="checkbox"/>
	604	GONG et al., "Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss," <u>PNAS</u> , 100(18):10417-10422 (2003).	<input type="checkbox"/>
	605	GREENBERG et al., "Alzheimer disease's double-edged vaccine," <u>Nat. Med.</u> , 9(4):389-390 (2003).	<input type="checkbox"/>
	896	GROSS et al., "Microvascular specializations promoting rapid interstitial solute dispersion in nucleus tractus solitarius," <u>Am J Physiol Regul Integr Comp Physiol</u> , 259:R1131-R1138 (1990).	<input type="checkbox"/>
	694	GUPTA et al., "Adjuvants for human vaccines—current status, problems, and future prospects," <u>Vaccine</u> , 13(14):1263-1275 (1995).	<input type="checkbox"/>
	606	HAASS, C., "New hope for Alzheimer disease vaccine," <u>Nat Med.</u> , 8(11):1195-1196 (2002).	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/544,093		
		Filing Date	August 1, 2005		
		First Named Inventor	Yednock, Ted		
		Art Unit	1649		
		Examiner Name	Emch, Gregory		
Sheet	14	of	27	Attorney Docket Number	15270C-009820US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	807	HARA et al., "Development of a safe oral A β vaccine using recombinant adeno-associated virus vector for Alzheimer's disease," <i>J. Alzheimer's Disease</i> , 6:483-488 (2004).	<input type="checkbox"/>
	664	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , pages 71-82 (1998).	<input type="checkbox"/>
	931	HARLOW et al., eds., <i>Antibodies: A Laboratory Manual</i> , page 98 (1998).	<input type="checkbox"/>
	741	HIRSCHFIELD et al., "Amyloidosis: new strategies for treatment," <i>Int. J. Biochem. & Cell Biol.</i> , 35:1608-1613 (2003).	<input type="checkbox"/>
	607	HOCK et al., "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <i>Nat. Med.</i> , 8(11):1270-1275 (2002).	<input type="checkbox"/>
	662	IDA et al., "Analysis of Heterogeneous β A4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot Assay," <i>J. Biol. Chem.</i> , 271(37):22908-22914 (1996).	<input type="checkbox"/>
	887	IDUSOGIE et al., "Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc," <i>J. Immunology</i> , 164:4178-4184 (2000).	<input type="checkbox"/>
	608	IRIZARRY et al., "Alzheimer disease therapeutics," <i>J. Neuropathol. Exp. Neurol.</i> , 60(10):923-928 (2001).	<input type="checkbox"/>
	929	JANSEN et al., "Use of Highly Encapsulated <i>Streptococcus pneumoniae</i> Strains in a Flow-Cytometric Assay for Assessment of the Phagocytic Capacity of Serotype-Specific Antibodies," <i>Clinical & Diagnostic Lab. Immunol.</i> , 5(5):703-710 (1998).	<input type="checkbox"/>
	609	JANUS et al., "Transgenic mouse models of Alzheimer's Disease," <i>Physiol. Behav.</i> , 73(5):873-886 (2001).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete If Known

Application Number	10/544,093
Filing Date	August 1, 2005
First Named Inventor	Yednock, Ted
Art Unit	1649
Examiner Name	Emch, Gregory
Attorney Docket Number	15270C-009820US

Sheet 15

of

27

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	640	JUNG et al., "Alzheimer's Beta-amyloid Precursor Protein Is Expressed on the Surface of Immediately Ex Vivo Brain Cells: a Flow Cytometric Study," <i>J. Neurosci. Res.</i> , 46(3):336-348 (1996).	<input type="checkbox"/>
	792	KAJKOWSKI et al., "β-Amyloid Peptide-induced Apoptosis Regulated by a Novel Protein Containing a G Protein Activation Module," <i>J. Biol. Chem.</i> , 276(22):18748-18756 (2001).	<input type="checkbox"/>
	834	KALBACK et al., "APP Transgenic Mice Tg2576 Accumulate Aβ Peptides That Are Distinct from the Chemically Modified and Insoluble Peptides Deposited in Alzheimer's Disease Senile Plaques," <i>Biochemistry</i> , 41:922-928 (2002).	<input type="checkbox"/>
	729	KASCSAK et al., "Mouse Polyclonal and Monoclonal Antibody to Scrapie-Associated Fibril Proteins," <i>J. Virology</i> , 61(12):3688-3693 (1987).	<input type="checkbox"/>
	895	KHATOON et al., "Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer's disease and control brains," <i>FEBS Letters</i> , 351:80-84 (1994).	<input type="checkbox"/>
	863	KIMCHI et al., "Analysis of cerebral amyloid angiopathy in a transgenic mouse model of Alzheimer disease using in vivo multiphoton microscopy," <i>J. Neuropath. Exp. Neurol.</i> , 60(3):274-279 (2001).	<input type="checkbox"/>
	843	KLYUBIN et al., "Anti-Aβ Antibodies Prevent Block of Long-Term Potentiation in the CA1 Area of Rat Hippocampus <i>In Vivo</i> by naturally Produced Aβ Oligomers," <i>Neurobiology of Aging</i> , 25:S224-S225, abstract P2-004, pages S224-S225 (2004).	<input type="checkbox"/>
	628	KOFLER et al., "Mechanism of Allergic Cross-Reactions—III. cDNA Cloning and Variable-Region Sequence Analysis of Two IgE Antibodies Specific for Trinitrophenyl," <i>Mol. Immunology</i> , 29(2):161-166 (1992).	<input type="checkbox"/>
	794	KOFLER et al., "Immunoglobulin κ Light Chain Variable Region Gene Complex Organization and Immunoglobulin Genes Encoding Anti-DNA Autoantibodies in Lupus Mice," <i>J. Clin. Invest.</i> , 82:852-860 (1988).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	16	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	627	KRISHNAN et al., "Correlation Between the Amino Acid Position of Arginine in VH-CDR3 and Specificity for Native DNA Among Autoimmune Antibodies ^{1,2} ," <u>J. Immunol.</u> , 157(6):2430-2439 (1996).	<input type="checkbox"/>
	826	KUBY, J., eds., page 123 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	<input type="checkbox"/>
	888	KUBY, J., eds., pages 108-109, 131-132 from <i>Immunology, Third Edition</i> , W.H. Freeman & co., (1997).	<input type="checkbox"/>
	695	KUO et al., "Water-soluble A β (N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains," <u>J. Biol. Chem.</u> , 271(8):4077-4081 (1996).	<input type="checkbox"/>
	833	KUO et al., "Comparative Analysis of Amyloid- β Chemical Structure and Amyloid Plaque Morphology of Transgenic Mouse and Alzheimer's Disease Brains," <u>J. Biol. Chem.</u> , 276(16):12991-12998 (2001).	<input type="checkbox"/>
	734	KURASHIMA et al., "Production of Monoclonal Antibody against Amyloid Fibril Protein and Its Immunohistochemical Application," <u>Appl. Pathol.</u> , 3(1-2):39-54 (1985).	<input type="checkbox"/>
	816	LaDu et al., "Isoform-specific Binding of Apolipoprotein E to β -Amyloid," <u>J. Biol. Chem.</u> , 269(38):23403-23406 (1994).	<input type="checkbox"/>
	651	LANDOLFI et al., "The Integrity of the Ball-and Socket Joint Between V and C Domains Is Essential for Complete Activity of a Humanized Antibody," <u>J. Immunology</u> , 166(3):1748-1754 (2001).	<input type="checkbox"/>
	755	LAVIE et al., "EFRH-Phage Immunization of Alzheimer's Disease Animal Model Improves Behavioral Performance in Morris Water Maze Trials," <u>J. Molecular Neuroscience</u> , 24:105-113 (2004).	<input type="checkbox"/>
	743	LICASTRO et al., "Is immunotherapy an effective treatment for Alzheimer's disease?," <u>Immunity & Aging</u> , 1:1-2 (2004).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	17	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	727	LINKE, "Monoclonal antibodies against amyloid fibril protein AA. Production, specificity, and use for immunohistochemical localization and classification of AA-type amyloidosis," <u>J. Histochemistry and Cytochemistry</u> , 32(3):322-328 (1982).	<input type="checkbox"/>
	889	LIU et al., "Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis," <u>Proc. Natl. Acad. Sci.</u> , 95:13266-13271 (1998).	<input type="checkbox"/>
	665	LO et al., "High level expression and secretion of Fc-X fusion proteins in mammalian cells," <u>Protein Engineering</u> , 11(6):495-500 (1998).	<input type="checkbox"/>
	904	MAMIKONYAN et al., "Anti-A β ₁₋₁₁ Antibody Binds to Different β -Amyloid Species, Inhibits Fibril Formation, and Disaggregates Preformed Fibrils but Not the Most Toxic Oligomers," <u>J. Biol. Chem.</u> , 282(31) 22376-22386 (2007).	<input type="checkbox"/>
	666	MANDEL et al., "Clinical trials in neurological disorders using AAV vectors: promises and challenges," <u>Curr. Opin. Mol. Ther.</u> , 6(5):482-490 (2004).	<input type="checkbox"/>
	913	MANNING et al., "Genetic Immunization with Adeno-Associated Virus Vectors Expressing Herpes Simplex Virus Type 2 Glycoproteins B and D," <u>Journal of Virology</u> , 71(10):7960-7962 (1997).	<input type="checkbox"/>
	742	MANOJ et al., "Approaches to Enhance the Efficacy of DNA Vaccines," <u>Critical Rev. Clin. Lab. Sci.</u> , 41(1):1-39 (2004).	<input type="checkbox"/>
	731	MARHAUG et al., "Monoclonal hybridoma antibodies to human amyloid related protein SAA," <u>Clin. Exp. Immunol.</u> , 50(2):390-396 (1982).	<input type="checkbox"/>
	744	MAROTTA et al., "Overexpression of amyloid precursor protein A4 (β -amyloid) immunoreactivity in genetically transformed cells: Implications for a cellular model of Alzheimer amyloidosis," <u>PNAS</u> , 86:337-341 (1989).	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	18	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	610	MATTSON et al., "Good and bad amyloid antibodies," <i>Science</i> , 301(5641):1845-1849 (2003).	<input type="checkbox"/>
	732	MAURY et al., "Immunohistochemical Localization of Amyloid in Finnish Hereditary Amyloidosis with Antibodies to Gelsolin Peptides," <i>Laboratory Investigation</i> , 64(3):400-404 (1991).	<input type="checkbox"/>
	611	MCLAURIN et al., "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues and 4-10 and inhibit cytotoxicity and fibrillogenesis," <i>Nat Med.</i> , 8(11):1263-1269 (2002).	<input type="checkbox"/>
	822	Merriam-Webster online medical dictionary, entry for "cure", accessed September 5, 2006.	<input type="checkbox"/>
	612	MONSONEGO et al., "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer's disease," <i>J. Clin. Invest.</i> , 112(3):415-422 (2003).	<input type="checkbox"/>
	613	MONSONEGO et al., "Immunotherapeutic approaches to Alzheimer's disease," <i>Science</i> , 302(5646):834-838 (2003).	<input type="checkbox"/>
	886	MORGAN et al., "The N-terminal end of the C ₂ domain of chimeric human IgG1 anti-HLA-DR is necessary for C1q, Fc γ RII and Fc γ RII binding," <i>Immunology</i> , 86:319-324 (1995).	<input type="checkbox"/>
	841	OKIE, S., "Promising Vaccine Targets Ravager of Minds," <i>Washington Post</i> , page A01, 5/8/01.	<input type="checkbox"/>
	808	OKURA et al., "Nonviral A β DNA vaccine therapy against Alzheimer's disease: Long-term effect and safety," <i>PNAS</i> , 103(25):9619-9624 (2006).	<input type="checkbox"/>
	652	ORLANDI et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," <i>PNAS</i> , 86:3833-3837 (1989).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	19	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	614	PAGANETTI et al., "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid," <i>J. Neurosci. Res.</i> , 46(3):283-293 (1996).	<input type="checkbox"/>
	615	PALLITTO et al., "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity," <i>Biochemistry</i> , 38(12):3570-3578 (1999).	<input type="checkbox"/>
	654	PANKA et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies," <i>PNAS</i> , 85:3080-3084 (1998).	<input type="checkbox"/>
	829	PARDRIDGE et al., "The Blood-Brain Barrier: Bottleneck in Brain Drug Development," <i>J. Am. Soc. Exp. Neurotherapeutics</i> , 2:3-14 (2005).	<input type="checkbox"/>
	682	PARNETTI et al., "Cognitive Enhancement Therapy for Alzheimer's Disease, The Way Forward," <i>Drugs</i> , 53(5):752-768 (1997).	<input type="checkbox"/>
	653	PAUL, W. E., eds., <i>Fundamental Immunology</i> , Third Edition, pages 292-295, Raven Press, New York (1993).	<input type="checkbox"/>
	933	PCT International Preliminary Examination Report of 02/09/2004 for application PCT/US01/46587.	<input type="checkbox"/>
	919	PCT Written Opinion of 12/14/04 for application PCT/US04/02856.	<input type="checkbox"/>
	937	PCT International Preliminary Report on Patentability (Chapter I) of 09/16/2005 with Written Opinion of 05/09/2005 for application PCT/US04/007503.	<input type="checkbox"/>
	806	PCT Search Report of 8/11/06 for application PCT/US2006/002837.	<input type="checkbox"/>
	850	PCT Search Report of 8/8/06 for application PCT/US2005/045515.	<input type="checkbox"/>
Examiner Signature			Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	20	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	938	PCT International Preliminary Report on Patentability (Chapter II) of 04/27/2006 for application PCT/US04/007503.	<input type="checkbox"/>
	872	PCT Search Report of 4/6/06 and Written Opinion of 4/8/06 for application PCT/US04/44093.	<input type="checkbox"/>
	903	PCT Search Report of 10/01/2007 and Written Opinion of 10/01/2007 for application PCT/US07/09499.	<input type="checkbox"/>
	774	PEETERS et al., "Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates," <i>J. Immunological Methods</i> , 120:133-143 (1989).	<input type="checkbox"/>
	890	PEREZ et al., "The β -Amyloid Precursor Protein of Alzheimer's Disease Enhances Neuron Viability and Modulates Neuronal Polarity," <i>J. Neurosci.</i> , 17(24):9407-9414 (1997).	<input type="checkbox"/>
	616	PFEIFER et al., "Cerebral hemorrhage after passive anti-A β immunotherapy," <i>Science</i> , 298(5597):1379 (2002).	<input type="checkbox"/>
	733	PHELPS et al., "Development and Characterization of Monoclonal Antibodies Specific for Amylin," <i>Hybridoma</i> , 15(5):379-386 (1996).	<input type="checkbox"/>
	864	PIERA et al., "Cytokines as adjuvants: effects on the immunogenicity of NeuAc alpha 2-GalNAc alpha-O-Ser/Thr (sialyl-Tn)," <i>Int. J. Cancer</i> , 55(1):148-152 (1993).	<input type="checkbox"/>
	877	PLUCKTHUN, A., "Mono- and Bivalent Antibody Fragments Produced in <i>Escherichia coli</i> : Engineering, Folding and Antigen Binding," <i>Immunological Reviews</i> , 130:151-188 (1992).	<input type="checkbox"/>
	837	Press Release, "Alzheimer's vaccine developer awarded Potamkin Prize," <i>American Academy of Neurology</i> , 5/7/01.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/544,093	
			Filing Date	August 1, 2005	
			First Named Inventor	Yednock, Ted	
			Art Unit	1649	
			Examiner Name	Emch, Gregory	
Sheet	21	of	27	Attorney Docket Number	15270C-009820US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	751	PROBERT et al., "Spontaneous inflammatory demyelinating disease in transgenic mice showing central nervous system-specific expression of tumor necrosis factor α ," <i>PNAS</i> , 92:11294-11298 (1995).	<input type="checkbox"/>
	809	QU et al., "A β_{42} gene vaccination reduces brain amyloid plaque burden in transgenic mice," <i>J. Neurological Sciences</i> , 244:151-158 (2006).	<input type="checkbox"/>
	641	RACKE et al., "Exacerbation of Cerebral Amyloid Angiopathy-Associated Microhemorrhage in Amyloid Precursor Protein Transgenic Mice by Immunotherapy Is Dependent on Antibody Recognition of Deposited Forms of amyloid β ," <i>J. Neurosci.</i> , 25(3):629-636 (2005).	<input type="checkbox"/>
	928	RAMMENSEE, H.G., "Chemistry of peptides associated with MHC class I and class II molecules," <i>Current Opinion in Immunology</i> , 7:85-96 (1995).	<input type="checkbox"/>
	638	Research Corporation Technology News, "THP and SangStat Partner to Develop Humanized Polyclonal Antibody Drugs," 11/11/02.	<input type="checkbox"/>
	626	"Researchers Develop Blood Test to Diagnose Alzheimer's- Type Changes in Mice," downloaded from www.businesswire.com on 12/15/04.	<input type="checkbox"/>
	926	RODRIGUEZ et al., "Enfermedad de Alzheimer. Situación Actual y Estrategias Terapéuticas" (Alzheimer Disease: present situation and therapeutic strategies), <i>Rev Cubana Med</i> [online], 38(2):134-142 (1999).	<input type="checkbox"/>
	838	ROSENBERG, R. N., "The Potamkin Prize for Pick's, Alzheimer's Disease and Related Disorders," pages 1-5.	<input type="checkbox"/>
	865	ROSES, A.D., "Apoplipoprotein E alleles as risk factors in Alzheimer's disease," <i>Annu. Rev. Med.</i> , 47:387-400 (1996).	<input type="checkbox"/>
	655	RUDIKOFF et al., "Single amino acid substitution altering antigen-binding specificity," <i>PNAS</i> , 79:1979-1983 (1982).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/544,093
				Filing Date	August 1, 2005
				First Named Inventor	Yednock, Ted
				Art Unit	1649
				Examiner Name	Emch, Gregory
Sheet	22	of	27	Attorney Docket Number	15270C-009820US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	851	SALDANHA et al., "A single backmutation in the human KIV framework of a previously unsuccessfully humanized antibody restores the binding activity and increases the secretion in cos cells," <i>Molecular Immunology</i> , 36:709-719 (1999).	<input type="checkbox"/>
	759	SCHENK et al., "Current progress in beta-amyloid immunotherapy," <i>Curr. Opin. Immunology</i> , 16(5):599-606 (2004).	<input type="checkbox"/>
	617	SCHMID, R. É., "Study suggest Alzheimer vaccine fix," from www.msnbc.com/news, pages 1-5 (2002).	<input type="checkbox"/>
	768	SCHMITT et al., "Interactions of the alzheimer β amyloid fragment ₍₂₅₋₃₅₎ with peripheral blood dendritic cells," <i>Mechanisms of Ageing and Development</i> , 94:223-232 (1997).	<input type="checkbox"/>
	629	SEIDL et al., "Predominant V _H genes expressed in innate antibodies are associated with distinctive antigen-binding sites," <i>PNAS</i> , 96:2262-2267 (1999).	<input type="checkbox"/>
	618	SELKOE, D. J., "Alzheimer's disease is a synaptic failure," <i>Science</i> , 298(5594):789-791 (2002).	<input type="checkbox"/>
	622	SERGEANT et al., "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach," <i>J. Neurochem</i> , 85(6):1581-1591 (2003).	<input type="checkbox"/>
	856	SEUBERT et al., "Antibody Capture of Soluble A β does not Reduce Cortical A β Amyloidosis in the PDAPP Mouse," <i>Neurodegenerative Diseases</i> , 5:65-71 (2008).	<input type="checkbox"/>
	818	SHINKAI et al., "Amyloid β -Proteins 1-40 and 1-42(43) in the Soluble Fraction of Extra- and Intracranial Blood Vessels," <i>Ann. Neurol.</i> , 38:421-428 (1995).	<input type="checkbox"/>
	828	Signet Laboratories, Inc., Product data sheet for mouse monoclonal clone 6E10, revised 7/13/05.	<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/544,093	
			Filing Date	August 1, 2005	
			First Named Inventor	Yednock, Ted	
			Art Unit	1649	
			Examiner Name	Emch, Gregory	
			Attorney Docket Number	15270C-009820US	
Sheet	23	of	27		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	697	SMALL et al., "Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease," <u>PNAS</u> , 97(11):6037-6042 (2000).	<input type="checkbox"/>	
	620	SOLOMON, B., "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology," <u>J. Neural Transm. Suppl.</u> , 62:321-325 (2002).	<input type="checkbox"/>	
	621	SOLOMON, B., "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease," <u>DNA and Cell Biology</u> , 20(11):697-703 (2001).	<input type="checkbox"/>	
	950	SOLOMON et al., "Fast induction of anti- β -amyloid peptide immune response," <u>Research and Practice in Alzheimer's Disease</u> , 6:260-264 (2002).	<input type="checkbox"/>	
	874	SOTO et al., "The conformation of Alzheimer's beta peptide determines the rate of amyloid formation and its resistance to proteolysis," <u>Biochem. J.</u> , 314:701-707 (1996).	<input type="checkbox"/>	
	678	SOUDER et al., "Overview of Alzheimer's disease," <u>Nurs. Clin. N. Am.</u> , 39:545-559 (2004).	<input type="checkbox"/>	
	914	SPELLERBERG et al., "DNA Vaccines Against Lymphoma," <u>Journal of Immunology</u> , 159:1885-1892 (1997).	<input type="checkbox"/>	
	939	Supplementary Partial European Search Report of 04/10/2007 for European Application 04720353.4-1222.	<input type="checkbox"/>	
	907	TANG et al., "Genetic immunization is a simple method for eliciting an immune response," <u>Nature</u> , 356:152-154 (1992).	<input type="checkbox"/>	
	839	TRAVIS, J., "A Vaccine for Alzheimer's Disease?," <u>Science News Online</u> , 156(2) pages 1-3 downloaded from Internet (1999).	<input type="checkbox"/>	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	24	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	857	TRAVIS, J., "Saving the Mind Faces High Hurdles," <i>Science</i> , 309:731-734 (2005).	<input type="checkbox"/>
	767	TRIEB et al., "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <i>Neurobiology of Aging</i> , 17(4):541-547 (1996).	<input type="checkbox"/>
	844	UniProtKB/Swiss-Prot entry P18525, pages 1-3 downloaded from http://www.expasy.org/cgi-bin/niceprot.pl/printable?ac=P18525 on 2/8/97, "HV54_Mouse" (11/1/90).	<input type="checkbox"/>
	815	URMONEIT et al., "Cerebrovascular Smooth Muscle Cells Internalize Alzheimer Amyloid Beta Protein via a Lipoprotein Pathway: Implications for Cerebral Amyloid Angiopathy," <i>Laboratory Investigation</i> , 77(2):157-166 (1997).	<input type="checkbox"/>
	700	VALLEIX et al., "Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family," <i>Kidney International</i> , 61:907-912 (2002).	<input type="checkbox"/>
	775	VAN DEN DOBBELSTEEN et al., "Characteristics of Immune Responses to Native and Protein Conjugated Pneumococcal Polysaccharide Type 14," <i>Scand. J. Immunol.</i> , 41:273-280 (1995).	<input type="checkbox"/>
	835	VAN LEUVEN, F., "Single and multiple transgenic mice as models for Alzheimer's disease," <i>Progress in Neurobiology</i> , 61:305-312 (2000).	<input type="checkbox"/>
	936	VANDERSTICHELE et al., "Standardization of Measurement of B-amyloid(1-42) in Cerebrospinal Fluid and Plasma," <i>Int. J. Exp. Clin. Invest.</i> , 7(4):245-258 (2000).	<input type="checkbox"/>
	690	VICKERS, J. C., "A Vaccine Against Alzheimer's Disease," <i>Drugs Aging</i> , 19(7):487-494 (2002).	<input type="checkbox"/>
	800	VIDANOVIC et al., "Effects of nonionic surfactants on the physical stability of immunoglobulin G in aqueous solution during mechanical agitation," <i>DIE PHARMAZIE</i> , 58(6):399-404 (2003).	<input type="checkbox"/>

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/544,093
		Filing Date	August 1, 2005
		First Named Inventor	Yednock, Ted
		Art Unit	1649
		Examiner Name	Emch, Gregory
		Attorney Docket Number	15270C-009820US
Sheet	25	of	27

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	623	WALSH et al., "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo," <u>Nature</u> , 416(6880):535-539 (2002).	<input type="checkbox"/>
	801	WANG, W., "Instability, stabilization, and formulation of liquid protein pharmaceuticals," <u>Int. J. Pharmaceutics</u> , 185(2):129-188 (1999).	<input type="checkbox"/>
	624	WASHINGTON UNIVERSITY IN ST. LOUIS SCHOOL OF MEDICINE, "Study gives Clues to Working of Anti-Alzheimer Antibody," downloaded from www.medicine.wustl.edu/~wumpa/news on 12/15/04.	<input type="checkbox"/>
	676	Webster's New World Dictionary, page 1387, therapeutic (1988).	<input type="checkbox"/>
	688	Webster's New World Dictionary of American English, Third College Edition, page 1078 (1988).	<input type="checkbox"/>
	765	WEINER, H. L., "Oral tolerance: immune mechanisms and treatment of autoimmune diseases," <u>Immunology Today</u> , 18:335-343 (1997).	<input type="checkbox"/>
	739	WEINREB et al., "NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded," <u>Biochemistry</u> , 35(43):13709-13715 (1996).	<input type="checkbox"/>
	625	WHITE et al., "Immunotherapy as a therapeutic treatment for neurodegenerative disorders," <u>J. Neurochem.</u> , 87(4):801-808 (2003).	<input type="checkbox"/>
	749	Wikipedia definition of "epitope" printed from internet on 4/26/06.	<input type="checkbox"/>
	752	Wikipedia definition of "antigen" printed from internet on 4/26/06.	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/544,093
				Filing Date	August 1, 2005
				First Named Inventor	Yednock, Ted
				Art Unit	1649
				Examiner Name	Emch, Gregory
(Use as many sheets as necessary)				Attorney Docket Number	15270C-009820US
Sheet	26	of	27		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	753	Wikipedia definition of "route of administration including parenteral" printed from Internet on 4/26/06.	<input type="checkbox"/>
	916	WINBLAD et al., "Hints of a therapeutic Vaccine for Alzheimer's?" <i>Neuron</i> , 38:517-519 (2003).	<input type="checkbox"/>
	897	WHITCOMB et al., "Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain," <i>Am J Physiol Gastrointest Liver Physiol</i> , 259:G687-G691 (1990).	<input type="checkbox"/>
	894	WU et al., "Expression of immunogenic epitopes of hepatitis B surface antigen with hybrid flagellin proteins by a vaccine strain of <i>Salmonella</i> ," <i>PNAS</i> , 86:4726-4730 (1989).	<input type="checkbox"/>
	900	Wyeth, Annual Review 2005: Creating Value...Advancing Health (February 27, 2006).	<input type="checkbox"/>
	909	XIANG et al., "Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines," <i>Immunity</i> , 2(2):129-135 Abstract (1995).	<input type="checkbox"/>
	728	YAMADA et al., "Generation and Characterization of Rat Monoclonal Antibodies Against Human Serum Amyloid A," <i>Scand. J. Immunol.</i> , 46(2):175-179 (1997).	<input type="checkbox"/>
	917	YANKNER et al., "Neurotrophic and Neurotoxic effects of Amyloid β Protein: Reversal by Tachykinin Neuropeptides," <i>Science</i> , 250:279-282 (1990).	<input type="checkbox"/>
	793	ZAMEER et al., "Single Chain Fv Antibodies against 25-35 Peptide Fragment of Amyloid- β : Potential Therapeutic for Alzheimer's Disease," Abstract P4-420, Page S593, presented at Poster Session P4:Therapeutics and Therapeutic Strategies-Therapeutic Strategies, Amyloid-Based, also <i>Neurobiology of Aging</i> , 25(Suppl. 2): p S593 (July 2004).	<input type="checkbox"/>
	825	ZHANG et al., "Specialized Applications, Purification of Recombinant Proteins and Study of Protein Interaction by Epitope Tagging," <i>Current Protocols in Mol. Biol.</i> , Supp 41, pages 10.15.1 through 10.15.9 (1998).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				<i>Application Number</i>	10/544,093
				<i>Filing Date</i>	August 1, 2005
				<i>First Named Inventor</i>	Yednock, Ted
				<i>Art Unit</i>	1649
				<i>Examiner Name</i>	Emch, Gregory
Sheet	27	of	27	<i>Attorney Docket Number</i>	15270C-009820US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	810	ZHANG et al., "A novel recombinant adeno-associated virus vaccine reduces behavioral impairment and β -amyloid plaques in a mouse model of Alzheimer's disease," <u>Neurobiology of Disease</u> , 14:365-379 (2003).	<input type="checkbox"/>

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.